<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00537862</url>
  </required_header>
  <id_info>
    <org_study_id>CERL080AKR02</org_study_id>
    <nct_id>NCT00537862</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients</brief_title>
  <official_title>Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients ; A Prospective, Open Label, Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of enteric-coated mycophenolate sodium&#xD;
      (EC-MPS) in a cyclosporine microemulsion based regimen with C2 monitoring in de novo kidney&#xD;
      transplant recipients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy &amp; safety of enteric-coated mycophenolate sodium combined with cyclosporine microemulsion &amp; corticosteroids assessed by overall survival at 6 months, biopsy proven acute rejection, graft loss, adverse events and serious adverse events.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of full dose of EC-MPS assessed by dose reduction &amp; treatment discontinuation rates due to adverse events</measure>
  </secondary_outcome>
  <enrollment type="Actual">200</enrollment>
  <condition>Kidney Transplant</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteric-Coated Mycophenolate Sodium (EC-MPS)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Korean Males and females aged 18 to 65 years.&#xD;
&#xD;
          -  Recipients of first, living unrelated or living related non-HLA identical donor kidney&#xD;
&#xD;
          -  Transplant, treated with cyclosporine microemulsion (Cs-ME) as primary&#xD;
             immunosuppressant.&#xD;
&#xD;
          -  Females of childbearing potential must have a negative serum pregnancy test within 7&#xD;
             days prior to randomization. Effective contraception must be used during the trial and&#xD;
             for 6 weeks following discontinuation of the study medication but at least for four&#xD;
             months after randomization, even where there has been a history of infertility.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Second or subsequent kidney transplant or multi-organ recipients (e.g. kidney and&#xD;
             pancreas) or previous transplant with any other organ.&#xD;
&#xD;
          -  Kidneys from cadaveric donors or HLA identical living related donors.&#xD;
&#xD;
          -  Patients with any known hypersensitivity to enteric coated Mycophenolate sodium&#xD;
             (EC-MPS) or other components of the formulation (e.g. lactose).&#xD;
&#xD;
          -  Patients with thrombocytopenia (&lt; 75,000/mm3), with an absolute neutrophil count of&#xD;
             &lt;1,500/mm3, and/or leukocytopenia (&lt;4,000/mm3 ), or hemoglobin &lt; 6g/dL .&#xD;
&#xD;
          -  Patients who have received any investigational drug within 30 days prior to study&#xD;
             entry.&#xD;
&#xD;
          -  Patients with a history of malignancy within the last five years, except for&#xD;
             successfully excised squamous or basal cell carcinoma of the skin.&#xD;
&#xD;
          -  Females of childbearing potential who are planning to become pregnant, who are&#xD;
             pregnant and/or lactating, who are unwilling to use effective means of contraception.&#xD;
&#xD;
          -  Existence of any surgical or medical condition, other than the current transplant,&#xD;
             which in the opinion of the investigator might significantly alter the absorption,&#xD;
             distribution, metabolism or excretion of study medication, and/or presence of severe&#xD;
             diarrhea, active peptic ulcer disease, or uncontrolled diabetes mellitus.&#xD;
&#xD;
          -  Patients with clinically significant infection requiring continued therapy.&#xD;
&#xD;
          -  Known positive HIV status.&#xD;
&#xD;
          -  Positive HBsAg test, or Hepatitis C positive with advanced liver disease or with&#xD;
             clinical or pathological diagnosis of cirrhosis.&#xD;
&#xD;
          -  Evidence of drug and/or alcohol abuse&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>(614-735)</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daegu</city>
        <zip>(700-712)</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daegu</city>
        <zip>(700-721)</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jeollanam-do</city>
        <zip>(501-757)</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>(110-744)</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>(120-752)</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>(137-701)</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>(138-736)</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>October 1, 2007</study_first_submitted>
  <study_first_submitted_qc>October 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2007</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Transplant Patients</keyword>
  <keyword>Immunosuppresion</keyword>
  <keyword>Enteric-coated mycophenolate sodium</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

